Core Viewpoint - The company reported a revenue decline in the first three quarters of 2025, but achieved profitability in net profit and non-recurring net profit [1] Financial Performance - The company achieved a revenue of 351 million yuan in the first three quarters, representing a year-on-year decrease of 2.44% [1] - The net profit attributable to the parent company was 27.63 million yuan, marking a turnaround from loss to profit year-on-year [1] - The non-recurring net profit was 4.32 million yuan, also indicating a year-on-year turnaround from loss to profit [1] - The basic earnings per share were 0.07 yuan [1]

就上述事项，公司拟对《浙江莎普爱思药业股份有限公司章程》（以下简称 "《公司章程》"）部分条款进行如下修订： | | | | | | 修订前 | | | | | | | | | | | | 修订后 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第 六 | 条 | 公 | 司 | 注 | 册 | 资 | 本 | 为 | 人 | 民 | 币 | 第 六 | 条 | 公 | 司 | | 册 | 本 | 注 | 为 人 民 币 | 资 | | 375,925,005 | | | | | | | 元。(以中国证券登记结算 | | | | | | 374,126,505 | | | 元。(以中国证券登记结算 | | | | | | | | | | | | 有限责任公司上海分公司的数据为 | | | | | | | | | | | | 有限责任公司上海分公司的数据为 | | | | ...

近日，浙江莎普爱思药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局（以下简称"国家药监局"）核准签发的玻璃酸钠滴眼液《药品补充 申请批准通知书》。现将相关情况公告如下： 一、药物的基本情况 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-064 浙江莎普爱思药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次获批的玻璃酸钠滴眼液，用于干眼症，缓解干眼症状。 截至目前，该项目累计研发投入约658.89万元人民币。 三、对公司的影响、后续安排及风险提示 公司本次获得玻璃酸钠滴眼液的《药品补充申请批准通知书》，进一步丰富 了公司的产品线，有助于提升公司产品的市场竞争力。 药品名称：玻璃酸钠滴眼液 剂型：眼用制剂 规格：0.1%（5ml:5mg） 注册分类：化学药品 药品批准文号：国药准字H20258230 上市许可持有人:浙江莎普爱思药业股份有限公司 审批结论: 根据《中华人民共和国药品管理法》及有关规定，经审查，本品 此次申请事项符合药品注册的 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-063 浙江莎普爱思药业股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第二次临时股东会 召开的日期时间：2025 年 11 月 19 日 10 点 00 分 召开地点：浙江省平湖市经济开发区新明路 1588 号浙江莎普爱思药业股份 有限公司办公楼五楼董事会会议室。 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月19日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 19 日 至2025 年 11 月 19 日 采用上海证券交易所网络投票系统， ...

浙江莎普爱思药业股份有限公司第六届董事会审计委员会第七次会议文件 决议 浙江莎普爱思药业股份有限公司董事会 第六届董事会审计委员会第七次会议决议 会议时间: 2025年10月30日上午9:30 会议主持人:陈胜群 出席会议人员：颜世富、林凯 2、审议通过《关于2025年第三季度报告的议案》。 审计委员会认为：公司的财务报告具备真实性，完整性和准确性。涉及的重要会计 判断的事项符合规定，不存在欺诈、舞弊行为及重大错报的情况，同意将本议案提交董 事会审议。 （表决结果：同意 3 票、反对 0 票、弃权 0 票） 召开方式：通讯 会议情况：应出席3人，实际出席3人，符合审计委员会议事规则 会议记录人：王雨 根据浙江莎普爱思药业股份有限公司《审计委员会工作细则》的相关规定，根据 审计委员会主任委员陈胜群先生提议，审计委员会于2025年10月28日以电话或邮件等方 式通知了审计委员会的全体委员，于2025年10月30日召开第六届董事会审计委员会第七 次会议。 审计委员会全体委员以投票表决的形式全票通过如下审议： 1、审议通过《关于豁免第六届董事会审计委员会第七次会议通知期限的议案》。 经全体董事审议和表决，同意豁免公司 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-061 浙江莎普爱思药业股份有限公司 第六届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江莎普爱思药业股份有限公司(以下简称"公司")第六届董事会第十一次会议于 2025年10月30日上午以通讯方式召开。本次董事会已于2025年10月28日以电子邮件、电 话、微信等方式通知全体董事、高级管理人员。本次会议由董事长林弘立先生主持，会 议应出席董事9人，实际出席董事9人，公司高级管理人员均知悉本次会议相关情况。本 次会议的召开符合《中华人民共和国公司法》和《浙江莎普爱思药业股份有限公司章程》 等有关规定，会议决议合法、有效。 二、董事会会议审议情况 经全体董事审议，通过了如下议案： (表决情况：同意票9票、反对票0票、弃权票0票) 2、审议通过《关于2025年第三季度报告的议案》。 同意并对外披露《浙江莎普爱思药业股份有限公司2025年第三季度报告》。 本议案已经第六届董事会审计委员会第七次会议审议通过。 ...

Financial Performance - The company's operating revenue for the third quarter was ¥114,539,032.74, a decrease of 6.54% compared to the same period last year[4]. - The total profit for the year-to-date period reached ¥25,365,780.91, with a net profit attributable to shareholders of ¥27,632,247.92[4]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥17,364,632.37 for the third quarter[4]. - Total operating revenue for the first three quarters of 2025 was CNY 350,629,873.70, a decrease of 2.14% compared to CNY 359,402,017.18 in the same period of 2024[20]. - Net profit for the first three quarters of 2025 was CNY 27,627,752.51, a turnaround from a net loss of CNY 28,400,706.00 in the same period of 2024[22]. - The company reported a total profit of CNY 25,365,780.91 for the first three quarters of 2025, compared to a total loss of CNY 22,988,834.03 in the previous year[22]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥60,020,426.83, representing a significant increase of 417.50%[5]. - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $422.92 million, an increase from $406.77 million in the same period of 2024, representing a growth of about 4%[24]. - The net cash flow from operating activities significantly improved to $60.02 million in 2025, compared to $11.60 million in 2024, indicating a substantial increase in operational efficiency[24]. - Total cash outflow for operating activities was approximately $362.90 million in 2025, a decrease from $395.17 million in 2024, indicating better cost management[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,131,853,844.83, reflecting a 1.22% increase from the end of the previous year[5]. - Total current assets increased to ¥418,032,263.40 from ¥366,665,116.02, a growth of approximately 14.0%[15]. - Total liabilities decreased slightly to CNY 513,251,593.45 from CNY 516,587,993.08[20]. - Non-current assets totaled ¥1,713,821,581.43, down from ¥1,739,587,919.89, a decrease of approximately 1.5%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 28,285[12]. - Shanghai Yanghe Industrial Co., Ltd. holds 20.82% of shares, with 78,249,836 shares pledged[12]. - Chen Dekang, a natural person, holds 11.67% of shares, totaling 43,871,004 shares[12]. Earnings Per Share - The basic earnings per share for the third quarter was ¥0.01, unchanged from the previous year[5]. - The diluted earnings per share for the third quarter was also ¥0.01, consistent with the previous year[5]. - Basic earnings per share for the first three quarters of 2025 was CNY 0.07, compared to a loss of CNY 0.08 in the same period of 2024[22]. Cost Management - The company has implemented cost control measures, resulting in a reduction in management expenses compared to the previous year[9]. - Total operating costs decreased significantly to CNY 336,856,292.82 from CNY 401,137,647.70, representing a reduction of approximately 16.06%[21]. - Research and development expenses decreased to CNY 14,861,974.29 from CNY 44,765,811.58, a reduction of approximately 66.8%[21]. Government Subsidies - The company reported a significant increase in government subsidies recognized, amounting to ¥1,583,793.41 for the year-to-date period[7]. Investment Activities - Cash outflow from investment activities totaled approximately $127.50 million in 2025, a decrease from $282.94 million in 2024, reflecting a reduction in capital expenditures[25]. - The net cash flow from investment activities was negative at -$85.68 million in 2025, an improvement from -$188.69 million in 2024, suggesting better investment management[25]. - The company received approximately $40.47 million from other investment-related cash inflows in 2025, a significant increase from $10.09 million in 2024, reflecting improved investment returns[25]. Financial Reporting - The company did not apply new accounting standards for the first time in 2025, maintaining consistency in financial reporting[26].

浙江莎普爱思药业股份有限公司 ZhejiangShapuaisiPharmaceuticalCo.，Ltd. (603168) 章程 (2025 年 10 月修订) | | | 第一章 总则 公司通过有限公司整体变更以发起方式设立；公司在浙江省市场 监督管理局注册登记，取得营业执照。统一社会信用代码： 91330000146644116H。 2 第一条 为维护浙江莎普爱思药业股份有限公司(以下简称"公司")、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中国 共产党党章》（以下简称"《党章》"）、《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上海证券交易所股票上市规则》以及其他有关规 定，制定本章程。 第二条 公司系依照《公司法》、《证券法》和其他有关规定成立的股份有 限公司。 第三条 公司于 2014 年 6 月 9 日经中国证券监督管理委员会(以下简称"中 国证监会")批准，首次向社会公众发行人民币普通股 1，635 万股， 于 2014 年 7 月 2 日在上海证券交易所(以下简称"证券交易所") 上市。 第四条 公司注册名称 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the third quarter of 2025 compared to the previous year, indicating potential challenges in its financial performance [1] Financial Performance - In the third quarter of 2025, the company achieved an operating income of 115 million yuan, a year-on-year decrease of 6.54% [1] - The net profit attributable to shareholders was 5.7694 million yuan, with a basic earnings per share of 0.01 yuan [1] - For the first three quarters of 2025, the company reported an operating income of 351 million yuan, down 2.44% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 27.6322 million yuan, with a basic earnings per share of 0.07 yuan [1]

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]